GlassScriptPhysician profile
Nami O Khulusi
NPI 1841361771
$6,721.82
in general payments reported to CMS, 2019-2025
34 companies · $755 in 2025
The $755 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $1,150 · 2021: $930 · 2022: $974 · 2023: $864 · 2024: $822 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,441.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,219.84 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,086.85 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Abbvie INC. | $1,010.30 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $899.95 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $380.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.68 | 2019-2024 | Jardiance |
| Pfizer INC. | $248.54 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $240.09 | 2019-2023 | Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $206.05 | 2019-2025 | Lagevrio |
| Phathom Pharmaceuticals, INC. | $198.27 | 2024-2025 | Voquezna |
| Currax Pharmaceuticals LLC | $131.95 | 2019-2025 | Contrave |
| Corcept Therapeutics | $102.61 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $78.99 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $78.06 | 2019-2020 | |
| Amarin Pharma, INC. | $68.55 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $54.99 | 2019-2020 | |
| Amgen INC. | $54.22 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $53.80 | 2022-2024 | |
| Medicure Pharma INC. | $51.65 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.84 | 2022 | |
| Genentech USA, INC. | $27.02 | 2020-2021 | |
| Allergan, INC. | $26.34 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $26.05 | 2019 | |
| Horizon Therapeutics Plc | $23.45 | 2019 | |
| Vivus LLC | $17.35 | 2024 | Qsymia |
| Ibsa Pharma INC. | $15.93 | 2024 | Licart, Tirosint |
| Janssen Pharmaceuticals, INC | $15.54 | 2021 | |
| Covis Pharma Gmbh | $14.99 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.50 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.41 | 2021 | |
| Glaxosmithkline, LLC. | $13.17 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.80 | 2019 | |
| Boston Scientific Corporation | $11.62 | 2021 | |
| Eisai INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nami Khulusi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.